A significant proportion of new drugs under development contain high potency active pharmaceutical ingredients (HPAPIs). The market of HPAPIs is increasing, with expected growth in the global arena of about $17.8 billion by 2018. However, due to its inherent cytotoxicity, HPAPIs present handling challenges.
Current statistics show that one in three people have a life-long risk of developing cancer. There is little scientific evidence currently available relating to whether working with cytotoxic drugs actually increases the risk of developing cancer or not.
In sterile pharmacy compounding, the goal of the pharmacist or pharmacy technician is to protect the compounded sterile preparation from cross-contamination.
Esco Pharma is pleased to launch our latest range of isolators specifically engineered to meet the growing demands of pharmacy compounding (503A and 503B) industry in the United States.
Pharmacy compounding has been present since the beginning of time. It is essential in cases such as limited dosage strengths and dosage forms, drug allergies to certain ingredients, paediatrics, chemotherapy and veterinary medicine.
The platform design with pre-proven engineering provides a perfect solution to meet a potent product formulation application with the shortest engineering and fastest delivery time.
Esco Pharma, building on the success of our suite of Aseptic/Containment Isolators, is proud to launch our Containment Barrier Isolator (CBI) range of aseptic/containment isolators. The Esco CBI retains the same functionality and platform engineering that Esco Pharma pioneered whilst adding more innovative features.